Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13
- Drug Discovery
- Technical Know How
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 415
A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025. The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the bodyâ€™s immune system and destroy cancer cells. The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF. Our technology, which shows potential for fighting cancer by enhancing oneâ€™s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.
IPSCIO Record ID: 544
Technology –The term Technology shall mean (a) any United States or foreign patents that claim two-gene combination cancer vaccines and related technology that issue from, or claim priority to, United States patent application serial number 08/838,702 entitled Combination Immunogene Therapy or United States patent application serial number 09/826,025 entitled Combination Immunogene Therapy (or similar name) and related applications including continuations, continuations-in-part, divisional applications and requests for continuing examination (collectively, the Combination Immunogene Therapy Patent Applications).
IPSCIO Record ID: 26298
IPSCIO Record ID: 367305
Patent rights, proprietary information and know-how relate to our HyperAcute immunotherapy technology.
The patents include
Radioisotope concentrator methods and compositions;
Radiation enhanced gene therapy for treatment of tumors;
Differential inactivation of nucleic acids by chemical modification;
Herpes simplex virus amplicon mini-vector gene transfer system;
Methods and compositions for inducing complement destruction of tissue;
Human suppressor TRNA oligonucleotides and methods of use for same;
DNA Methylation associated with genetic instability in retroviral vector producing cells;
HSV-ATM Vector for ataxia-telangiectasia gene therapy;
Activation of ganciclovir for generating anti-tumor responses;
Dual adenoviral delivery of transgenes.
The inventions and Know-how include
Polyphosphokinase gene to attempt gene therapy by creating polymers of radioactive phosphate;
Sodium iodide symporter related efforts;
Improved Herpes simplex vectors;
Humanized T4 endonuclease V gene therapy for UV photoproduct damage;
Animal model of cancer in a(1,3)galactosyltransferase knockout mice.
IPSCIO Record ID: 29247
IPSCIO Record ID: 3044
During 2003, two lawsuits were filed challenging the Licensor's ownership of this intellectual property. The value of the intellectual property will be diminished if either of the pending lawsuits regarding the same is successful. Governors of the University of Alberta filed against the Licensor and the Licensee in August 2003. The University of Alberta claims, among other things, that the Licensee failed to remit the payment of the Universityâ€™s portion of the monies paid by the Licensor to the Licensee for the CIT technology purchased by the Licensor.
IPSCIO Record ID: 318779
IRX-2 is an allogeneic, reproducible, primary, cell-derived biologic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as a subcutaneous injection around lymph node beds.
IRX-2 is produced under current good manufacturing practices, or cGMP, following stimulation of a specific population of human peripheral blood mononuclear cells (PMBC) using a specified mitogen. These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes. Cytokine production induced by the employed mitogen mimics that seen after brisk stimulation of human immune cells by an immunogenic pathogen or an infection. PBMCs are obtained from FDA-licensed blood banks meeting all criteria for further human use.
The Licensee is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer.
IPSCIO Record ID: 344582
The patents are titled
(a) U.S. Patent Application Number 60/092,672, filed July 13, 1998, entitled â€œCancer Treatment Using Antibodies to Aminophospholipidsâ€ (UT SOUTHWESTERN File Reference UTSD0549PZ1);
(b) U.S. Patent Application Number 60/110,608, filed December 2, 1998, entitled â€œCancer Treatment Using Antibodies to Aminophospholipidsâ€ (UT SOUTHWESTERN File Reference UTSD0549PZ2);
(c) U.S. Patent Application Number 09/351,543, filed July 12, 1999, entitled â€œ Cancer Treatment Methods Using Antibodies to Aminophospholipidsâ€ (UT SOUTHWESTERN File Reference UTSD0549);
(d) U.S. Patent Application Number 09/351,862, filed July 12, 1999, entitled â€œ Cancer Treatment Kits Using Antibodies to Aminophospholipidsâ€ (UT SOUTHWESTERN File Reference UTSD0549-1);
Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (â€œPSâ€), a highly immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then â€œflipsâ€ and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. Bavituximab targets and binds to PS to block this immunosuppressive pathway and simultaneously activates adaptive immunity, thereby enabling the immune system to recognize and fight the tumor.
IPSCIO Record ID: 195780
Licensor owns the rights to Patent Application Serial No. 62/478520 filed 03-29-17 â€œMethods of Re-Activating Dormant Memory Cells with Anticancer Activityâ€ and commercially named â€œMemoryMuneâ€.
The patent licensed provides means to recapitulate a natural immune response ex vivo through activation of innate immune cells, and subsequently utilizing products generated by said cells to stimulate adaptive immune cells to acquire ability to induce killing or inhibiting proliferation of cells expressing oncogenic transformations. In one embodiment of the invention, innate immune cells are activated with stimuli capable of inducing production of cytokines associated with induction of immunity to intracellular abnormalities; said cytokines are further administered to adaptive immune cells in a patient in need of treatment.
Licensee intends to develop products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.
Developing the novel immunological use of mifepristone in the area of oncology adds another weapon in the fight against cancer using the patientâ€™s own immune system. Natural killer cells are a unique arm of the immune system that is capable of killing cancer cells without prior sensitization. The findings that mifepristone is capable of reducing cancer associated suppression of the natural killer cell compartment, we believe, positions mifepristone as a potentially valuable therapeutic in utilization of the immune system to kill tumors.
IPSCIO Record ID: 266679
This research and collaboration agreement is to analyze and assess the potential clinical utility of certain compounds owned or licensed by Licensee.
Product means a preparation containing a Verified Compound having at least one indication for which Success has been predicted by Licensor under the Program.
Our Personalized Oncology Solutions (â€œPOS) business which provides services to physicians and patients looking for information to help guide the development of a personalized treatment plans.
Our Translational Oncology Solutions (â€œTOS) business, which provides services to pharmaceutical and biotech companies seeking personalized approaches to drug development that will lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs.
Our technology platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs. Our process technology involves the
implantation of human tumor fragments in immune compromised mice;
expansion of the original human tumor into a larger colony of mice through the passage of the tumor to subsequent generations of mice;
treatment of the implanted mice with oncology drugs;
measurement of tumor growth inhibition in treated mice relative to a control group of mice to determine the response of the tumor to the drug.
Our process is used for our POS business to test numerous drugs or drug combinations against a single patientâ€™s tumor to determine which therapy results in the most efficacious response from the tumor.
IPSCIO Record ID: 312594
In April 2020, the Court granted in part Licensorâ€™s motion and entered a final judgment awarding royalties on Licenseeâ€™s sales of Yescarta* from December 13, 2019 through the expiration of the Patent in August 2024.
Yescarta is a trademark of Licensee. Yescarta, a CAR T cell therapy, involves (i) harvesting T cells from the patientâ€™s blood, (ii) engineering T cells to express cancer-specific receptors, (iii) increasing the number of engineered T cells and (iv) infusing the functional cancer-specific T cells back into the patient.
IPSCIO Record ID: 29158
IPSCIO Record ID: 26619
O6-Benzylguanine (O6-BG) is a chemosensitizer that is designed to overcome resistance to a significant class of commonly used chemotherapeutic agents known as O6-alkylating agents. In preclinical animal studies, treatment with O6-BG increased the anti-tumor activity of these agents in brain, colon, and prostate cancers, as well as in melanoma. A Phase II development program began in 1999. O6-BG, a series of related compounds and a gene therapy that the Company believes will enhance the effectiveness of a class of currently used chemotherapeutic agents known as O6-alkylating agents. O6-BG and related compounds are small molecules for intravenous administration in the treatment of cancer. The Company believes O6-BG to be capable of destroying the resistance of cancer cells to a class of chemotherapeutic agents, O6-alkylating agents. The Company believes that the effectiveness of alkylating chemotherapeutic agents against various tumors such as brain, prostate, colon cancers, melanoma and lymphoma is limited due to the ability of tumor cells to repair the DNA damage caused by the O6-alkylating agents, because the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT), protects tumor cells by repairing the tumor cell DNA.
The Company believes that O6-BG inactivates the AGT protein in a variety of cancers thereby overcoming resistance to theO6-alkylating agents.